Myth vs Fact: Blincyto Edition

Blinatumomab (Blincyto) in India
Blinatumomab (Blincyto) in India

Blincyto is a Bispecific T-cell engager (BiTE) immunotherapy used for the treatment of certain B-cell precursor acute lymphoblastic leukemia (ALL). Since it works differently from chemotherapy, it has led to curiosity and confusion. These confusions lead to misconceptions to patients, so here’s the article to burst the myth and present the facts.


MYTH: Blincyto (Blinatumomab) works for all types of leukemia

FACT: Blincyto is indicated in adults and children above one month old with:

  • CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.  

  • Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). 

  • CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. 



MYTH: Side-effects of Blincyto are same as that of chemotherapy

FACT: The side-effects of Blincyto are not the same as that of chemotherapy. The side-effects of Blincyto are cytotoxic release syndrome, neurological toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome and infections.



MYTH: Blincyto weakens the body’s immune system

FACT: Blincyto doesn’t weaken but modulates the body’s immune system. Infections can occur during the treatment, so careful monitoring is required and prophylactic medications have to be given.



MYTH: Patients are hospitalized throughout the Blincyto

FACT: Patients are hospitalized only during dosage schedules for continuous monitoring and noticing any severe adverse effects. Once the patient is stabilized with the treatment, the treatment can be taken in the home complying with all the protocols.



MYTH: There is no benefit of taking Blincyto before stem cell transplantation.

FACT: Taking Blincyto before the stem cell transplant is very beneficial because the chances of long-term remission increases and enhances overall treatment outcomes.



MYTH: Blincyto is extremely painful treatment

FACT: Blincyto is administered in the form of intravenous infusion. Sometimes, its side-effects may be a little disturbing but not the actual Blincyto treatment.



MYTH: Discontinue the treatment permanently in case of neurological problems.

FACT: In most cases, the nerve related problems are temporary if noticed in the early stages and can be reversible. Prompt intervention always reduces the risk of long-term consequences.



Want to hear the updates of Blincyto? connect with us at 24/7QualityMeds.


References:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125557s032lbl.pdf


Location: India

Popular posts from this blog

Not All Immune Protection Starts with a Vaccine: What Makes Cytogam Different?

Image
Cytogam CMV 50 mg for Injection available in India  Most people are familiar with the two primary approaches used to protect the body against viral infections: vaccines and antiviral medications. Antiviral drugs work by targeting specific stages of a virus's life cycle. They interfere with the virus's ability to replicate, spread, or produce the proteins it needs to survive within the body. Vaccines, in contrast, help train the immune system to recognize and respond to a particular pathogen before an infection occurs, enabling the body to build its own defense mechanisms. However, there is a third approach that is often overlooked. It is neither a vaccine nor an antiviral drug, yet it plays an important role in protecting certain high-risk patients. This approach is known as hyperimmune globulin therapy. Understanding the Basics Hyperimmune globulin therapy provides immediate immune protection by supplying antibodies that have already been formed. Unlike vaccines, which require...
Read more

Pemigatinib in India: Availability, Pricing & Access Pathways Explained

Image
Buy pemigatinib (Pemazyre) tablets in India For patients looking for pemigatinib in India , finding the medicine can involve a different process from purchasing a conventional prescription medicine from a local pharmacy. Pemigatinib, sold under the brand name Pemazyre, is an oral targeted therapy that inhibits fibroblast growth factor receptors (FGFR1, FGFR2 and FGFR3). It is used for specific cancers in which these pathways are altered, including previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement and relapsed or refractory myeloid/lymphoid neoplasms with an FGFR1 rearrangement. In India, access can involve individual-patient importation rather than routine retail pharmacy supply. Understanding the prescription, documentation, sourcing, storage, delivery and monitoring requirements can help patients and caregivers navigate the process more confidently. The Current Situation of Pemazyre in India Why This Therapy Is N...
Read more